Related Experiment Videos
Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study
1Department of Neurology, Neurological Institute, Kyushu University, Fukuoka, Japan.
Abstract:
Using the polymerase chain reaction, we quantitated the amount of human T-lymphotropic virus type I (HTLV-I) proviral DNA in peripheral blood mononuclear cells from 18 patients with HTLV-I--associated myelopathy/tropical spastic paraparesis; 17 HTLV-I carriers without HTLV-I--associated myelopathy/tropical spastic paraparesis, with or without other autoimmune or inflammatory diseases; and 19 seronegative control subjects. The HTLV-I proviral DNA was 10- to 100-fold higher in the patients and in the HTLV-I carriers without HAM/TSP who had autoimmune or inflammatory diseases than in the carriers without autoimmune or inflammatory diseases. The patients who had had onset of myelopathy at a younger age (15 to 39 years) had an extremely high level of HTLV-I proviral DNA in the early phase, as compared with findings in those with a late onset of myelopathy (at 44 to 61 years). The large increase in HTLV-I proviral DNA in peripheral blood mononuclear cells is presumably closely related to the development of autoimmune or inflammatory processes in HTLV-I carriers, including HTLV-I--associated myelopathy/tropical spastic paraparesis.
Insights
Higher human T-lymphotropic virus type I (HTLV-I) proviral DNA levels correlate with autoimmune diseases like HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Early-onset HAM/TSP shows extremely high early-phase HTLV-I DNA.
Area of Science:
- Virology
- Immunology
- Neurology
Background:
- Human T-lymphotropic virus type I (HTLV-I) is linked to neurological conditions.
- The exact viral load and its correlation with disease severity require further investigation.
Purpose of the Study:
- To quantify HTLV-I proviral DNA in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and compare it with carriers and controls.
- To explore the relationship between HTLV-I proviral DNA levels, disease onset, and autoimmune/inflammatory processes.
Main Methods:
- Polymerase chain reaction (PCR) was used to measure HTLV-I proviral DNA in peripheral blood mononuclear cells.
- Subjects included HAM/TSP patients, HTLV-I carriers (with or without other diseases), and seronegative controls.
Main Results:
- HTLV-I proviral DNA was significantly higher (10- to 100-fold) in HAM/TSP patients and carriers with autoimmune diseases compared to carriers without these conditions.
- Patients with early-onset myelopathy (<39 years) exhibited extremely high HTLV-I proviral DNA levels during the early phase of the disease.
Conclusions:
- Elevated HTLV-I proviral DNA in peripheral blood mononuclear cells is strongly associated with the development of autoimmune and inflammatory conditions in HTLV-I carriers.
- This finding suggests a critical role for viral load in the pathogenesis of HTLV-I-associated neurological disorders like HAM/TSP.